Skip to main content

Table 2 Standardized AUCs for clinical, serological, comorbidity and treatment serial measurements of persistent and nonpersistent patients

From: Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability

AUC for serial assessments Persistent-patients (n = 32) Nonpersistent patients (n = 43) P value
Clinical    
   Disease activity score (28 joints) 2.83 ± 1.45 3.04 ± 0.89 0.45
   66 swollen joint counts 3.65 ± 5.06 3.99 ± 2.86 0.72
   68 tender joint counts 4.02 ± 5.16 3.94 ± 2.74 0.94
   Physician global assessment of disease activity visual analogue scale 11.72 ± 16.46 12.24 ± 7.60 0.87
   Patient pain visual analogue scale 11.79 ± 11.42 12.77 ± 7.24 0.65
   Patient overall disease visual analogue scale 11.73 ± 12.3 13.19 ± 7.26 0.52
   Health assessment questionnaire 0.23 ± 0.36 0.36 ± 0.32 0.23
Serological    
   Erythrocyte sedimentation rate 16.99 ± 11.97 15.99 ± 9.67 0.69
   C-reactive protein 1.18 ± 1.52 0.73 ± 0.69 0.13
   Number of comorbidities/patient 1.33 ± 2.4 1.1 ± 1.48 0.62
Treatment    
   Number of DMARDs/patient 2.31 ± 0.71 2.47 ± 0.71 0.35
   Number of drugs for comorbidity/patient 1.81 ± 1.03 1.83 ± 0.88 0.90
   Number of total drugs/patient 4.38 ± 1.13 4.61 ± 1.17 0.39
  1. Data presented as the mean ± standard deviation. AUC, area under the curve; DMARD, disease-modifying antirheumatic drug.